CJC-1295 (with DAC): doses reported in published research

Sources checked 2026-10-07 · 3 cited studies (2 human, 1 animal, 0 cell culture)

CJC-1295 is a synthetic GHRH analog with a drug affinity complex (DAC) that binds albumin. Published dose data come from two small studies in healthy adults and one mouse study.

Human data: two small studies in healthy adults (2006). A phase 2 trial (NCT00267527) was terminated and its registry record lists no dose.

Studies in people (2)

Human Healthy adults aged 21-61, two randomized, placebo-controlled, double-blind ascending-dose trials (28 and 49 days)

Dose as reported: Four ascending single doses (first trial); 2 or 3 doses (second trial). The abstract names 30 and 60 µg/kg; the other dose levels are not listed in the abstract
Route: Subcutaneous
Frequency / duration: Single dose; or 2-3 doses given weekly or every other week

Source wording: CJC-1295 or placebo was administered sc in one of four ascending single doses in the first study and in two or three weekly or biweekly doses in the second study. particularly at doses of 30 or 60 microg/kg

Teichman SL, Neale A, Lawrence B et al.. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. J Clin Endocrinol Metab 2006. PubMed PMID 16352683 ↗

Human Healthy men aged 20-40

Dose as reported: 60 or 90 µg/kg
Route: Not stated in the abstract
Frequency / duration: Single dose; sampling before and 1 week after

Source wording: before and 1 wk after injection of either 60 or 90 microg/kg CJC-1295

Ionescu M, Frohman LA. Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog. J Clin Endocrinol Metab 2006. PubMed PMID 17018654 ↗

Animal studies (1)

Animal doses are listed exactly as the studies report them. They are not converted to human amounts here; doses do not translate between species by body weight.

Animal GHRH-knockout mice, from 1 week of age

Dose as reported: 2 µg per mouse
Route: Not stated in the abstract
Frequency / duration: Every 24, 48 or 72 h (separate groups) for 5 weeks

Source wording: Three groups of 1-wk-old GHRHKO mice were treated for 5 wk with 2 microg of CJC-1295 at intervals of 24, 48, and 72 h.

Alba M, Fintini D, Sagazio A et al.. Once-daily administration of CJC-1295, a long-acting growth hormone-releasing hormone (GHRH) analog, normalizes growth in the GHRH knockout mouse. Am J Physiol Endocrinol Metab 2006. PubMed PMID 16822960 ↗

Half-life

Human Estimated half-life 5.8-8.1 days in healthy adults after subcutaneous administration. Source wording: The estimated half-life of CJC-1295 was 5.8-8.1 d. Subcutaneous administration of CJC-1295
Teichman SL, Neale A, Lawrence B et al.. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. J Clin Endocrinol Metab 2006. PubMed PMID 16352683 ↗

A third report (PMID 19386527, 11 healthy men) does not state the amount given in its abstract.

About this page

Every figure above is copied from the cited source; the source wording is shown with each entry. Where a source does not state something, the page says so.
Only abstracts, open-access full texts, registry records and FDA labels were used, so details found only in a paywalled full text may be missing.
This page does not convert doses between species or into other measures, and gives no preparation or handling information.